When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...
Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results